<div id="readability-page-1">Intellia Therapeutics Inc ( (NTLA) ) has released its Q3 earnings. Here is a breakdown of the information Intellia Therapeutics Inc presented to its investors.<h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions </li><li> Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.</li></ul> Intellia Therapeutics, Inc. is a clinical-stage gene editing company leveraging CRISPR-based therapies to develop innovative treatments for unmet medical needs, primarily in the biotechnology sector. In its third quarter 2025 financial report, Intellia Therapeutics highlighted ongoing developments in its clinical trials, particularly the MAGNITUDE trials for nexiguran ziclumeran (nex-z) and the HAELO trial for lonvoguran ziclumeran (lonvo-z). The company also reported a significant cash position and financial results for the quarter. Key financial metrics from the report include a cash position of approximately $670 million, expected to fund operations into mid-2027. The company reported collaboration revenue of $13.8 million, an increase from the previous year, and a net loss of $101.3 million, which is an improvement from the previous year’s loss. Intellia also noted a decrease in research and development expenses. Strategically, Intellia is addressing challenges in its MAGNITUDE trials following a clinical hold by the FDA due to safety concerns, while continuing to advance its lonvo-z program with completed enrollment in the Phase 3 HAELO trial. The company anticipates presenting longer-term data at upcoming scientific meetings and is preparing for potential regulatory submissions. Looking ahead, Intellia remains focused on resolving the clinical hold issues with nex-z and advancing its pipeline, with expectations for regulatory submissions and potential commercial launches in the coming years.</div>

NTLA

Intellia Therapeutics Inc reported Q3 2025 financial results, highlighting a cash position of $670 million, collaboration revenue of $13.8 million, and a net loss of $101.3 million. The company is addressing FDA clinical hold issues in its MAGNITUDE trials and advancing its lonvo-z program. Intellia anticipates regulatory submissions and potential commercial launches in the coming years.

Intellia Therapeutics Reports Q3 2025 Financial Results